Red Light‐Responsive Upconverting Nanoparticles for Quantitative and Controlled Release of a Coumarin‐Based Prodrug

Brion, Anaïs; Chaud, Juliane; Léonard, Jérémie; Bolze, Frédéric; Chassaing, Stefan; Frisch, Benoı̂t; Heurtault, Béatrice; Kichler, Antoine; Specht, Alexandre

doi:10.1002/adhm.202201474

Cited by 11 publications

(13 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The uncaging quantum yield was determined in MeOH/H 2 O 9:1 in vol. for the DEACAS-DOG-Melph and in HEPES 10 mM, NaCl 150 mM, pH 7.2 for Liposomes formulated with the DEACAS-DOG-Melph, at 25 °C by comparison with the DEACAS- p -methoxybenzoic acid as previously reported by Brion et al in 2023 …”

Section: Methodsmentioning

confidence: 75%

“…Lp were diluted at 1/50 in water to determine Zeta-potential on a Zetasizer Nano-ZS as previously reported by Brion et al in 2023 …”

Section: Methodsmentioning

confidence: 99%

“…To measure the TBPe to 8 LRET efficiency E LRET , we proceeded as in Brion et al and evaluated E LRET from the excitation spectra of two types of Lps (see Figure S3C and S3D) loaded with the UC chromophore pair (Pd-TPTBP 20 μM, TBPe 200 μM) and with (a: Lp-UC- 8 ) or without (c: Lp-UC) the LRET acceptor ( 8 , 280 μΜ). A third type (b: Lp-Pd-TPTBP- 8 ) missing the TBPe (Pd-TPTBP 20 μM, 8 280 μM) was used to evaluate the luminescence signal upon direct 8 excitation.…”

Section: Methodsmentioning

confidence: 99%

“…To be able to use a red-light activation, the use of upconversion (UC) assisted photolysis has been recently explored to trigger drug delivery upon photolysis from nanocarriers in vivo. , UC is an anti-Stokes process able to convert photons into higher-energy, allowing for example, the conversion of red to blue light. UC systems based on triplet–triplet annihilation upconversion (TTA-UC) of organic chromophores have very recently been applied for life science applications. − In TTA-UC, photon energies absorbed by (at least) two donor chromophoresalso called “sensitizers”are transferred to emitter chromophoresalso called “annihilators”through collisions resulting in triplet–triplet energy transfer. Then, upon diffusion, two annihilators in their triplet excited state can collide producing one singlet excited state emitting luminescence − (see Figure S2A).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Photoactivatable Liposomes for Blue to Deep Red Light-Activated Surface Drug Release: Application to Controlled Delivery of the Antitumoral Drug Melphalan

Brion,

Chaud,

Klimezak

et al. 2023

Bioconjugate Chem.

Self Cite

View full text Add to dashboard Cite

Liposome-based nanoparticles able to release, via a photolytic reaction, a payload anchored at the surface of the phospholipid bilayer were prepared. The liposome formulation strategy uses an original drug-conjugated blue light-sensitive photoactivatable coumarinyl linker. This is based on an efficient blue light-sensitive photolabile protecting group modified by a lipid anchor, which enables its incorporation into liposomes, leading to blue to green light-sensitive nanoparticles. In addition, the formulated liposomes were doped with triplet−triplet annihilation upconverting organic chromophores (red to blue light) in order to prepare red light sensitive liposomes able to release a payload, by upconversion-assisted photolysis. Those light-activatable liposomes were used to demonstrate that direct blue or green light photolysis or red light TTA-UC-assisted drug photolysis can effectively photorelease a drug payload (Melphalan) and kill tumor cells in vitro after photoactivation.

show abstract

Section: Methodsmentioning

confidence: 75%

“…Lp were diluted at 1/50 in water to determine Zeta-potential on a Zetasizer Nano-ZS as previously reported by Brion et al in 2023 …”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Photoactivatable Liposomes for Blue to Deep Red Light-Activated Surface Drug Release: Application to Controlled Delivery of the Antitumoral Drug Melphalan

Brion,

Chaud,

Klimezak

et al. 2023

Bioconjugate Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The photopharmacology sector could also benefit from these spectral conversion techniques. Some up-conversion research in the biomedical sector [49,50] and specifically in the photopharmaceutical sector has already been described [51,52].…”

Section: A New Tool For Overcoming the Main Barriers Of Photopharmaco...mentioning

confidence: 99%

A Novel Photopharmacological Tool: Dual-Step Luminescence for Biological Tissue Penetration of Light and the Selective Activation of Photodrugs

Menéndez‐Velázquez¹,

García-Delgado²

2023

IJMS

View full text Add to dashboard Cite

Conventional pharmacology lacks spatial and temporal selectivity in terms of drug action. This leads to unwanted side effects, such as damage to healthy cells, as well as other less obvious effects, such as environmental toxicity and the acquisition of resistance to drugs, especially antibiotics, by pathogenic microorganisms. Photopharmacology, based on the selective activation of drugs by light, can contribute to alleviating this serious problem. However, many of these photodrugs are activated by light in the UV–visible spectral range, which does not propagate through biological tissues. In this article, to overcome this problem, we propose a dual-spectral conversion technique, which simultaneously makes use of up-conversion (using rare earth elements) and down-shifting (using organic materials) techniques in order to modify the spectrum of light. Near-infrared light (980 nm), which penetrates tissue fairly well, can provide a “remote control” for drug activation. Once near-IR light is inside the body, it is up-converted to the UV–visible spectral range. Subsequently, this radiation is down-shifted in order to accurately adjust to the excitation wavelengths of light which can selectively activate hypothetical and specific photodrugs. In summary, this article presents, for the first time, a “dual tunable light source” which can penetrate into the human body and deliver light of specific wavelengths; thus, it can overcome one of the main limitations of photopharmacology. It opens up promising possibilities for the moving of photodrugs from the laboratory to the clinic.

show abstract

Photoresponsive Drug Delivery Systems: Challenges and Progress

Yang,

Long,

Chu

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Photoresponsive drug delivery systems (PDDSs) have emerged as a promising toolbox for drug delivery, offering precise control over the site, duration, and dosage of light‐triggered medication. It allows controlled drug release, photo‐triggered targeting, diagnosis, and treatment, improving the precision and efficacy of therapies for various diseases. Despite progress in designing different PDDSs, clinical translation has been limited due to various obstacles. Herein, this review article focuses on three critical challenges of PDDSs: 1) accumulation at diseased lesions, 2) precision of light irradiation, and 3) penetration of light in tissues. Also, this article summarizes and discusses current advancements and strategies to address these challenges. Overall, it emphasizes the need to clarify the current challenges from bench to bedside and develop strategies to enhance therapeutic outcomes, increase compatibility and patient compliance, and unlock the possibilities in different clinical therapies.

show abstract

Red Light‐Responsive Upconverting Nanoparticles for Quantitative and Controlled Release of a Coumarin‐Based Prodrug

Abstract: Photolytic reactions allow the optical control of the liberation of biological effectors by photolabile protecting groups. The development of versatile technologies enabling the use of deep-

Cited by 11 publications

References 64 publications

Photoactivatable Liposomes for Blue to Deep Red Light-Activated Surface Drug Release: Application to Controlled Delivery of the Antitumoral Drug Melphalan

Photoactivatable Liposomes for Blue to Deep Red Light-Activated Surface Drug Release: Application to Controlled Delivery of the Antitumoral Drug Melphalan

A Novel Photopharmacological Tool: Dual-Step Luminescence for Biological Tissue Penetration of Light and the Selective Activation of Photodrugs

Photoresponsive Drug Delivery Systems: Challenges and Progress

Contact Info

Product

Resources

About